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1. Introduction 
In the last years new players have been revealed in cancer biology: microRNA (miRNAs or 
miRs) a class of small non coding RNAs (19-22 nts) able to regulate gene expression at post-
transcriptional level, binding through partial sequence homology mainly the 3’ UTR of 
target mRNAs, and causing block of translation and/or mRNA degradation.  
miRNAs are generated by an endogenous transcript, they represent approximately 1% of 
the genome of different species, and each of them has hundreds of different conserved or 
non conserved targets: it has been estimated that about 30% of the genes are regulated by at 
least one miRNA. miRNA genes, expressed in several organisms, including Homo Sapiens, 
are highly conserved across different species [1].  
This discovery resulted in a pattern shift in our understanding of gene regulation because 
miRNAs are now known to repress thousands of target genes and coordinate normal 
processes, including cellular proliferation, differentiation and apoptosis. They are highly 
specific for tissue and developmental stage, and play crucial functions in the regulation of 
important processes, such as development, and stress response. In the last few years, 
miRNAs have indeed taken their place in the complex circuitry of cell biology, revealing a 
key role as regulators of gene expression.  
In 2002, Croce and colleagues first demonstrated that a miRNA cluster was frequently 
deleted or downregulated in chronic lymphocytic leukemia. This discovery suggested that 
non-coding genes were contributing to the development of cancer, and paved the way for a 
closer investigation of miRNA loss or amplification in tumors.  
miRNAs expression profiling has indeed provided evidence of the association of these tiny 
molecules with tumor development, progression and response to therapy, suggesting their 
possible use as diagnostic, prognostic and predictive biomarkers. It has been demonstrated 
that miRNAs can act either as oncogenes or tumor suppressors, and more recently it has 
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been demonstrated that a miRNAs can exploit both functions according to the cellular 
context of their target genes. Another important issue concerns the role of miRNAs in 
regulating the interaction between cancer cells and the microenvironment with respect to 
neo-angiogenesis or tissue invasion and metastasis. 
Outgrowths of disseminated metastases remain the primary cause of mortality in cancer 
patients, but the molecular and cellular mechanisms regulating metastatic spread remain 
largely unknown. Metastatic processes involve multiple steps, including detachment from 
primary tumors, crossing the basement membrane barriers and extracellular matrix, 
intravasation into the circulation, survival within the vasculature, extravasation into distant 
tissues, and finally, establishment of secondary tumors [2] . These processes rely on 
coordinated spatio-temporal expression of various genes and finely regulated protein 
products, which govern the ability of tumor cells to successfully complete the intricate task, 
and the pivotal role of miRNAs in metastasis has emerged only recently.  
2. miRNAs biogenesis and mechanism of action 
miRNAs are generated by endonucleolytic cleavage of hairpin precursor transcripts by 
Dicer ribonuclease (RNase) III–like proteins and can direct the cleavage of target transcripts 
by Argonaute RNAse H–like proteins in a sequence-specific manner. miRNAs can also 
inhibit translation of target mRNAs. 
miRNAs are transcribed for the most part by RNA Polimerase II as long primary transcripts 
characterized by hairpin structures (pri-microRNAs), and part of them are transcribed as 
distinct transcriptional units. 50% of known miRNA genes are located nearby other 
microRNAs, supporting the hypothesis that clustered miRNAs, representing miRNA 
families which are commonly related in sequence and function, can be transcribed from 
their own promoters as polycistronic pri-microRNAs. 
According to their genomic localization, microRNAs can be classified in: 
a) exonic microRNAs located in non coding transcripts, b) intronic microRNAs located in 
non coding transcripts and  microRNA located in protein-coding trancripts, c) mixed 
miRNA genes that can be assigned to one of the above groups depending on the given 
splicing pattern. Exonic microRNAs are transcribed within the pri-miR (up to 1 kb long) 
containing both the 5’-cap and the 3’-poly-A tail. The miRNAs localized within introns of 
protein-encoding or -non-encoding genes have been denominated “miRtrons”. miRtrons are 
regulatory RNAs transcribed within the mRNA of the host gene generating a hairpin 
structure, recognized and cleaved by the spliceosome machinery without Drosha-mediated 
cleavage.  
The initial step in pri-miRNA processing (Figure 1) is performed in the nucleus by the 
enzymatic activity of an RNAse III-type protein called Drosha. Drosha is a highly conserved 
160 kDa protein containing two RNAse III domains and one double-strand RNA-binding 
domain. Drosha forms a huge complex, 500 kDa in D. melanogaster and 650 kDA in H. 
sapiens, known as Microprocessor complex, which generates a ~70-nucleotides precursor 
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miRNA (pre-miRNA) and contains the co-factor Di George syndrome critical region 8 
(DGCR8), also known as Pasha in D. melanogaster and C. elegans. 
 
Figure 1. An overview of microRNAs biogenesis and mechanism of action. 
The originated precursor molecules are then actively exported by a Ran-GTP and Exportin 
5-mediated mechanism to the cytoplasm, where the second step of pre-miRNA processing 
(dicing) is mediated by the RNAse III Dicer (~200 kDa), which acts in complex with the 
transactivating response RNA-binding protein (TRBP), or PACT (also known as PRKRA), 
and Argonaute (AGO1-4), generating a dsRNA of approximately 22 nucleotides, named 
miR:miR*. This dsRNA includes the mature miRNA guide, and the complementary 
passenger strand, the miRNA* (star miRNA) (many publications refer to the two strand pair 
as miR-3p/miR-5p, referring to the direction of the functional miRNA). Whereas one of the 
two strands is selected as guide strand according to thermodynamic properties, the 
complementary one is usually subjected to degradation. The so called miRNA* was initially 
thought to be the strand subjected to degradation, instead more recent evidence suggests 
that it does not simply represent a non-functional bioproduct of miRNA biogenesis, but it 
can be selected as a functional strand and play significant biological roles [3] .  
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More in details, guided by the sequence complementarity between the small RNA and the 
target mRNA, miRNA-RISC-mediated gene inhibition is commonly divided into three 
processes: (i) site-specific cleavage, (ii) enhanced mRNA degradation and (iii) translational 
inhibition. The first process, commonly defined as RNA interference (RNAi) and restricted 
to miRNAs with a perfect or near-perfect match to the target RNA, is a very rare event in 
mammals, where it is carried out exclusively by Ago2. By contrast, the other two processes 
are more commonly associated with mismatched miRNA/target sequences, which is the 
most likely scenario in mammals. The combination of these two processes is commonly 
defined as a non-cleavage repression, and can be carried out by any of the four mammalian 
Ago proteins [4] . However, the exact mechanism through which miRNAs can impair 
translation is still debated.  
Moreover, even though it is known that microRNAs mainly recognize complementary 
sequences in the 3’ untraslated regions (UTRs) of their target mRNAs, more recent studies 
have reported that they can also bind to the 5’UTR or the ORF [5-8] and, even more 
surprisingly, they can upregulate translation upon growth arrest conditions [9] .  
Finally, whereas the 5’ end of the microRNA (the so called “seed site”) has always been 
considered the most important for the binding to the mRNA, recently the target sites have 
been further divided into three main classes, according to grade and localization of the 
complementarity [10] : the dominant seed site targets (5′ seed-only), the 5′ dominant 
canonical seed site targets (5′ dominant) and the 3′ complementary seed site targets (3′ 
canonical).  
Considering the different rules regulating the interaction between a microRNA and its 
target mRNA, it is not surprising that each miRNA has the potential to target a large 
number of genes [11-14]. Conversely, an estimated 60% of the mRNAs have one or more 
evolutionarily conserved sequences that are predicted to interact with miRNAs. 
Bioinformatical analysis predicts that the 3′ UTR of a single gene is frequently targeted by 
several different miRNAs [11] . Many of these predictions have been validated 
experimentally, suggesting that miRNAs might cooperate to regulate gene expression (a list 
of computational tools for miRNA target prediction is reported in Table 1).  
 
name website
miRNA map http://mirnamap.mbc.nctu.edu.tw/ 
miRBASE http://mirbase.org/ 
microRNA http://www.microrna.org/microrna/home.do 
coGemiR http://www.cogemir.tigem.it/ 
miRGEN http://www.diana.pcbi.upenn.edu/miRGen.html 
deepBase http://www.deepbase.sysu.edu.cn 
Table 1. miRNA databases. 
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To complicate the already intricate scenario, it has been recently reported that miRNAs can 
bind to ribonucleoproteins in a seed sequence and a RISC-independent manner and then 
interfere with their RNA binding functions (decoy activity) [15] . Three studies have 
reported that miRNAs can also regulate gene expression at the transcriptional level by direct 
binding to the DNA [16-18].  
Overall, these data show the complexity and widespread regulation of gene expression by 
miRNAs that should be taken into consideration when developing miRNA-based therapies. 
3. Metastasis 
The most deleterious effect of cancer is metastases development, indeed tumor metastasis is 
the primary cause of death in cancer patients. The ability to metastasize is a hallmark of 
malignant tumors [19] . Metastases represent the end point of a multi-step process that 
consists of local invasion through surrounding extracellular matrix and stromal cells, 
intravasation into the blood vessels, survival in the circulation, extravasation, and 
colonization of distant tissues [20]. Each step in this process represents a physiological 
barrier that must be overcome by the tumor cell to successfully metastasize. Malignant cells 
overcome these barriers through the accumulation of genetic and epigenetic changes, 
including modifications in microRNA expression profiles. Despite great improvement in the 
knowledge of metastasis biology, the molecular mechanisms which underlie this intricate 
process are still not completely understood.  
Tumor cells can invade surrounding tissues as cohesive multicellular units or as individual 
cells, and individual cells can invade through the ‘amoeboid invasion’ or the ‘mesenchymal 
invasion’ programs [21] . Amoeboid movement depends mainly from Rho/ROCK 
expression, and is independent from adhesion and proteolytic degradation of ECM [22,23]. 
On the contrary, mesenchymal motility depends upon interaction of carcinoma cells with 
the extracellular matrix through integrin recruitment and upon pericellular ECM proteolysis 
of the moving cells. Cells that use this program to invade are characterized by an elongated 
and polarized morphology, achievable with an epithelial to mesenchymal transition (EMT). 
EMT, first described as typical of embryonic development, generates cells with 
mesenchymal features phenotypically similar to invading cells. The EMT transcriptional 
programme has been associated with activation of several key transcriptions factors, 
including Snail1 and Snail2 (Slug), Twist, ZEB-1-2, etc, which lead to the regulation of a 
series of proteins causing decrease of E-cadherin for disruption of adherent junctions, 
increase in N-cadherin and Met proto-oncogene to drive motility, as well as increase in 
MMPs and urokinase–type plasminogen activator/urokinase–type plasminogen receptor 
(uPA/uPAR) proteolytic systems to degrade 3D barriers [24,25].  
The overexpression of many of these EMT regulators have been shown to correlate with 
disease relapse and decreased survival in patients with breast, colorectal, and ovarian 
carcinomas, suggesting that the induction of EMT leads to more aggressive tumors and 
poorer clinical outcomes. 
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Once tumor cells have invaded local microenvironment, they should intravasate, survive in 
the circulation and extravasate at distant sites. To successfully perform these steps, they 
have to cross the pericyte and endothelial cell barriers that form the walls of microvessels. In 
order to overcome physical barriers which represent an obstacle to extravasation in tissues 
with low intrinsic microvessel permeability, primary tumors are capable of secreting factors 
that perturb these distant microenvironments and induce vascular hyperpermeability. The 
ability of the cancer cell to develop into a metastatic lesion at distant sites is the most 
limiting step in cancer metastasis formation. Indeed, the disseminated tumor cells may stay 
in a quiescent state for long time, probably due to incompatibilities with the foreign 
microenvironments that surround them [2]. Some have proposed that carcinoma cells can 
address the problem of an incompatible microenvironment at the metastatic site via the 
establishment of a “premetastatic niche” [26]. 
4. miRNAs and metastasis  
Remarkably, a regulatory role for miRNAs in metastasis has been recognized, and the term 
“metastamir” has been coined by Welch and colleagues to refer to those regulatory miRNAs 
not just involved in tumorigenesis, but specific in the promotion or suppression of various 
steps of metastasis [27]. To date, microRNAs have mostly been found to influence the initial 
stages of metastasis, affecting cell migration and invasion (Figure 2). Although a particular 
miRNA that specifically regulates cancer cell intravasation and extravasation has not yet 
been identified, it is still believed that these steps may also be regulated by miRNAs. 
 
 
Figure 2. microRNAs implicated in the regulation of EMT and cell migration.  
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Several miRNAs have been found to regulate the EMT process, and the most well-known 
among them is the miR-200 family, which includes miR-200a, miR-200b, miR-200c, miR-141 
and miR-429.  
miR-200 family is recognized as a master regulator of the epithelial phenotype by post 
transcriptionally suppression of the expression of the ZEB1 and ZEB2 EMT-inducing 
transcription factors in breast [28] and gastric cancer [29]. Acting in the opposite direction, 
ZEB1 and ZEB2, which promote not only tumor cell dissemination, but also the tumor-
initiating capacity, has been shown to transcriptionally repress miR-200 family members, 
thereby establishing a double negative feedback loop that causes the reinforcement of cells 
in either the mesenchymal or epithelial state [25]. This miR family, as others able to control 
epithelial–mesenchymal plasticity, is likely to also affect events at metastatic sites. Recently, 
the putative DNA methylation-associated inactivation of various miR-200 members has 
been described in cancer. miR-200 epigenetic silencing resulted to be not a static and fixed 
process, instead there can be a shift to hypermethylated or unmethylated 5'-CpG island 
status corresponding to the EMT and mesenchymal-epithelial-transition (MET) phenotypes, 
respectively. In fact, careful laser microdissection in human colon revealed that in normal 
colon mucosa crypts (epithelia) and stroma (mesenchyma) 5'-CpG island status are 
unmethylated and methylated at these loci, respectively, and that the colorectal tumors 
undergo selective miR-200 hypermethylation of their epithelial component. These findings 
indicate that the epigenetic silencing plasticity of the miR-200 family contributes to the 
evolving and adapting phenotypes of human tumors [30]. 
Unexpectedly, it was reported that overexpression of miR-200 enhances macroscopic 
metastases in mouse breast cancer models. These findings were surprising but provide yet 
another example of the opposing activities of some miRNAs [31]. miR-200 levels are 
indirectly downregulated by miR-103/107  that target Dicer, a key component of the miRNA 
processing machinery. Accordingly, miR-103/107 are associated with metastasis and poor 
outcome in human breast cancer [32]. 
The transcription factor ZEB1 can also repress the expression of stemness-inhibiting miR-203 
[33]. Recently, miR-203 was reported as a metastasis suppressor miRNA, targeting Slug [34] 
and Snail1 [35] and is often silenced in different malignancies including hepatocellular 
carcinoma, prostate cancer, oral cancer, breast cancer and hematopoietic malignancy. Snail1 
and Slug play a key role during the early step of EMT, activating expression of ZEB factors 
in a context-dependent manner. Functionally, ectopic expression of miR-203 in BT549 and 
MDA-MB-231 breast cancer cell lines caused cell cycle arrest and apoptosis and inhibited 
cell invasion and migration in vitro. Thus the miR-203 and miR-200 feedback loops control 
cell plasticity in epithelial homeostasis. Snail1 is also regulated by miR-30a in non-small cell 
lung cancer (NSCLC), where it is dowmodulated [36]. 
Opposite to miR-200 family, miR-221/222 family promotes a poorly differentiated 
mesenchymal-like phenotype in breast cancer, and is highly expressed in triple negative 
breast cancers that basally expressed EMT markers. Increasing miR-221 or miR-222 can 
affect various characteristics associated with EMT, including increased invasive capacity, 
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[37,38], and anoikis resistance [39]. Forced expression of miR-221/222 in luminal breast 
cancer cells causes a decrease in E-cadherin and an increase in the mesenchymal marker 
vimentin [40]. Luminal cells expressing miR-221/222 gained a more mesenchymal 
morphology and had increased migratory and invasive capacity [41]. Furthermore, miR-221 
and miR-222 can regulate angiogenesis, repressing the proliferative and angiogenic 
properties of c-Kit in endothelial cells [42]. In addition other miRNAs can manage EMT, 
such as the ZEB1- and ZEB2-suppressing miR-205 [28], which has also been shown to exert 
an oncosuppressive activity in breast cancer [43,44] prostate cancer [45] and melanoma [46]; 
and miR-27, which promotes EMT in gastric cancer cell directly targeting APC gene and 
activating the Wnt pathway [47].  
Recently, the inhibition of EMT by p53 has been described as a new mode of tumor 
suppression which presumably prevents metastasis. p53 activation down-regulates Snail via 
induction of the miR-34a/b/c genes, which directly target Snail transcription factor. Ectopic 
miR-34a expression caused down-regulation of Slug and ZEB1, as well as the stemness 
factors BMI1, CD44, CD133, OLFM4 and c-MYC, thus provoking MET. Conversely, the 
transcription factors Snail and ZEB1 repress miR-34a and miR-34b/c expression [48]. 
Recently it has been described that miR-34 suppress also c-MET in hepatocellular carcinoma 
[49] and in osteosarcoma cells [50]. 
EMT is characterized by cadherin switching (from E-cadherin to N-cadherin), that correlates 
with a profound change in cell phenotype and behavior. miR-9, identified as a new 
“metastomiR” and activated by MYC and MYCN, directly targets CDH1, the E-cadherin-
encoding messenger RNA, leading to increased cell motility and invasiveness, activation of β-
catenin signaling and upregulation of VEGF. Moreover, overexpression of miR-9 in non-
metastatic breast tumor cells enables these cells to form pulmonary micrometastases in mice, 
and in colorectal cancer cells it promotes cell motility [51]. Conversely, inhibition of miR-9 in 
highly malignant cells impairs metastasis formation [52].  
N-cadherin (CDH2) was proved to be a direct target of miR-145 by Gao P and coworkers 
[53]. miR-145, suppressing N-cadherin protein translation and indirectly downregulating 
also its downstream effector matrix metallopeptidase 9 (MMP9), suppresses metastases. It 
has been reported that miR-145 exerts its anti metastatic role by directly targeting also the 
metastatic gene mucin 1 [54] in breast cancer and VEGF in osteosarcoma cells [55]. Moreover, 
suppression of Mucin1 by miR-145 causes a reduction of β-catenin as well as the oncogenic 
Cadherin 11 [54]. Accordingly miR-145, acting as a metastasis suppressor, is stepwise 
downregulated in normal gastric mucosa, primary gastric cancers and their secondary 
metastases [53] , and in osteosarcoma in comparison to normal tissues [55].  
Several miRNAs such as miR-34a [56], miR-373 and miR-520c [57] and mir-328 [58] have 
been reported to regulate the cell-surface glycoprotein encoding gene CD44 (cell surface 
receptor for hyaluronan). Cell lines with high CD44+/CD24− cell numbers are 
basal/mesenchymal or myoepithelial types and are more invasive than other cell lines [59]. 
miR-520/373 has been also reported to directly target TGFBR2 and to induce the suppression 
of Smad-dependent expression of the metastasis-promoting genes parathyroid hormone-
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related protein, plasminogen activator inhibitor-1 and angiopoietin-like 4, thus impairing 
tumor cell invasion, in vitro and in vivo. Remarkably, decreased expression of miR-520c 
correlated with lymph node metastasis specifically in ER negative breast tumors [60]. 
Recently Han M and coworkers [61] demonstrated that miR-21 regulates epithelial-
mesenchymal transition phenotype and hypoxia-inducible factor-1α (HIF-1α) expression in 
sphere forming breast cancer stem cells (CSC). Indeed inhibition of miR-21 by antagomir led 
to reversal of EMT, down-expression of HIF-1α, as well as suppression of invasion and 
migration, which indicates a key role of miR-21 in regulating CSC-associated features.  
EMT is a profound change in cell phenotype that causes immotile epithelial cells to acquire 
traits such as motility, invasiveness, anoikis and the ability to adapt to environmental 
changes to continue to invade successfully. Mesenchymal motility program is characterised 
by elongated and polarized cell morphology and depends upon ECM proteolysis of the 
moving cells and from integrin interaction with the extracellular matrix. 
Urokinase, a serin protease, activating plasmin triggers a proteolysis cascade that, 
depending on the physiological environment, participates in extracellular matrix 
degradation. miR-193a/b overexpression in MDA-MB-231 and MDA-MB-435 breast 
carcinoma cells significantly reduced its direct target uPA protein amounts and inhibited 
cell invasion [62]. In an immunodeficient mouse model, miR-193b significantly inhibited the 
growth and dissemination of xenografted tumors [63]. The expression of miR-193b is 
downregulated in metastatic breast cancer, and this microRNA is in turn able to upregulate 
uPA expression and to contribute to the progression of breast cancer. Recently, miR-23b was 
reported to directly target uPA and c-MET and to decrease migration and proliferation of 
human hepatocellular carcinoma cells [64]. Plasminogen activation can be regulated also 
indirectly by mir-17/20 expression, which is usually downregulated in highly invasive 
breast cancer cell lines and node-positive breast cancer specimens [65]. microRNA17/20 
directly repressed IL-8 by targeting its 3' UTR, and inhibited cytokeratin 8 via the cell cycle 
control protein cyclin D1, a secreted plasminogen activator. Indeed cell-conditioned 
medium from microRNA17/20-overexpressing non invasive breast cancer cell MCF7 was 
sufficient to inhibit MDA-MB-231 cell migration and invasion [65]. The invasion-related 
urokinase receptor is also indirectly regulated by a miRNA. Indeed, oncogenic miR-21, 
elevated in different tumor types, included colorectal cancer [66] melanoma and breast 
cancer [67], post-transcriptionally regulates PDCD4, that can suppress invasion and 
intravasation, at least in part by inhibiting expression of uPAR gene via the transcription 
factors Sp1/Sp3. Thus, miR-21 is able to enhance cancer cell intravasation, extravasation and 
metastasis in addition to cell proliferation.  
The restoration in hepatocellular carcinoma cells of miR-122 that exerts some of its action via 
regulation of ADAM17 caused a dramatic reduction of in vitro migration, invasion, in vivo 
tumorigenesis, angiogenesis, and local invasion in the liver of nude mice [68]. Under the 
transcriptional control of HNF1A, HNF3A and HNF3B, miR-122 is specifically repressed in 
a subset of primary tumors that are characterized by poor prognosis [69]. 
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ADAM9 is directly target by miR-126, which expression is reduced in invasive ductal 
adenocarcinoma (IDA) and pancreatic cancer cell lines. Re-expression of miR-126 and 
siRNA-based knockdown of ADAM9 in pancreatic cancer cells resulted in reduced cellular 
migration, invasion, and induction of epithelial marker E-cadherin [70]. It also directly 
regulates the adaptor protein Crk that binds to several tyrosine-phosphorylated proteins, 
inhibiting cell growth by inducing cell cycle arrest in G0/G1 phase, migration and invasion 
in vitro as well as tumorigenicity and metastasis in vivo in gastric cancer [71].  
Matrix metalloproteinase-2 (MMP2), involved in matrix degradation and involved in 
angiogenesis, is directly regulated by miR-29b, whose down modulation promotes 
angiogenesis, invasion, and metastasis of hepatocellular carcinomas [72]. MMP2 was 
confirmed to be a miR-29b target apart from Mcl-1, COL1A1, and COL4A1 also in prostate 
cancer cells [73].  
miR-29c-targeted genes identified in nasopharyngeal carcinomas (NPC) encode extracellular 
matrix proteins, including multiple collagens and Laminin γ1, that are associated with 
tumor cell invasiveness in culture and increased metastasis in animal models and multiple 
human solid tumors as well as fibrillin SPARC [74]. Interestingly, introduction of miR-29c 
led to a reduced transcription of these genes in cultured cells, and the down-regulation of 
mir-29c level in NPC human cancer correlated with increase of target mRNAs, which could 
facilitate rapid matrix generation and renewal during tumor growth and the acquisition of 
tumor motility.  
It was demonstrated that miR-183 targets ezrin, an intermediate between the plasma 
membrane and the actin cytoskeleton involved, together with radixin, in epithelial cell 
morphogenesis and adhesion [75], and may play a central role in the regulation of migration 
and metastasis in breast cancer [76], osteosarcoma [77] and lung cancer [78]. miR-183 is 
markedly down-regulated in osteosarcoma cells and tissues compared with matching 
normal bone tissues and its expression levels significantly correlated with lung metastasis as 
well as with local recurrence of osteosarcoma [77]. 
miR-223 is overexpressed in metastatic gastric cancer cells and stimulates non metastatic 
gastric cancer cells to migrate and to invade. Mechanistically, miR-223, induced by the 
transcription factor Twist, post transcriptionally downregulates EPB41L3 expression, 
thought to be involved in tethering the F-actin cytoskeleton to membrane proteins. Another 
functional downstream target of miR-223 is FBXW7, shown to have important roles in 
regulating the stability of multiple oncoprotein substrates, including Cyclin E, c-MYC, 
Notch, c-Jun, and Mcl-1. Overexpression of miR-223 is associated with poor metastasis-free 
survival in primary gastric carcinomas [79], with lymph node metastasis in gastric cancer, 
and poorer prognosis in oesophageal squamous cell carcinoma patients [80]. 
Cells can move also through an “amoeboid invasion” program. This motility style is largely 
independent from cell-ECM contact and from proteolytic degradation of ECM from MMPs. 
Furthermore, cell-ECM attachments of amoeboid moving cells are not organized in large 
focal adhesions but are very diffuse, and much weaker cell-ECM attachments are required, 
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indeed, amoeboid movement cannot be blocked by inhibition of integrin function. The 
amoeboid invasion depends from Rho/ROCK expression, and their expression can be 
regulated also by miRNAs. 
miR-10b, the first miRNA described to be pro-metastatic by Ma and colleagues in 2007 [81], 
inhibits the translation of mRNA encoding HOXD10, increasing the expression of Rho C, 
and thus leading to tumor cell invasion and metastasis. Ectopic expression of this miRNA 
endowed non-aggressive human breast cancer cells with the capacity to become invasive, as 
well as seed distant micrometastases when implanted as xenografts in immunodeficient 
mice. miR-10b was down-regulated in most breast cancers in comparison with normal 
mammary tissues, whereas it was highly expressed in about 50% of breast metastatic 
tumors.  Induced by transcription factor Twist, miR-10b function as a metastasis driver in 
different types of cancer: i.e pancreatic [82], gastric [83] and colorectal [84] cancers.  
RhoA, another member of Ras homolog gene family, was described also as a target for miR-
155, a Smad4 regulated miR in breast cancer [85]. 
Mir-31 is able to inhibit multiple steps in the metastatic process: local invasion, one or more 
early post-intravasation events (intraluminal viability, extravasation efficiency and/or 
capacity to initially survive in the lung parenchyma), and metastatic colonization. MiR-31 
carries out its anti-metastatic function regulating three genes: Rho A, Integrin α5 and 
Radixin. Via suppression of Rho A, it is able to inhibit in vitro invasiveness [86,87]. Notably it 
also reduces Integrin α5, a key effector of the mesenchymal invasion program, causing 
concomitant inhibition of both single-cell invasion programs. Controlling expression of 
Radixin, miR-31 causes anoikis-mediated cell death. In agreement with these data, miR-31 
expression has been found to be attenuated in human breast [88-90], prostate [91], ovary [92], 
stomach [93,94] and bladder cancer [95]. Moreover miR-31 levels in primary human breast 
tumors were inversely associated with distant metastases [86]. Paradoxically, upregulation of 
miR-31 in human colorectal [96,97], liver [98] and head-and-neck tumors [99,100], as well as 
squamous cell carcinomas of the tongue [101] has also been observed [102] . 
ROCK1 and ROCK2, the downstream targets of Rho A and Rho C, are regulated by miR-
148a [103] and by miR-139 [104], respectively, which all behave as anti-metastatic miRNAs. 
Overexpression of miR-148a in gastric cancer cells [103] as well as in head and neck cancer 
cells  [105], and of miR-139 in hepatocellular carcinoma cells (HCC) [104], suppressed cell 
migration and invasion in vitro and lung metastasis formation in vivo. Accordingly, miR-
148a expression was suppressed in gastric cancer compared with their corresponding non 
tumor tissues, and the downregulated miR-148a was significantly associated with tumor 
node metastasis and miR-139 expression is reduced in metastatic HCC tumors compared 
with primary tumors. 
In addition, others miRNAs with prominent roles in breast cancer metastasis have been 
reported. 
The c-MYC regulated miR-17-92 cluster, which targets the connective tissue growth factor 
(CTGF) and the anti-angiogenic adhesive glycoprotein Thrombospondin 1 (TSP1) is shown 
to be elevated in metastatic breast cancer cells compared with nonmetastatic cells. miRNAs 
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belonging to this cluster, attenuating also the TGFβ signaling pathway, indirectly shut down 
clusterin and angiopoietin-like 4 expressions, thereby stimulating angiogenesis and tumor 
cell growth [106].  Accordingly, blockade of miR-17 is shown to decrease breast cancer cell 
invasion/migration in vitro and metastasis in vivo [107]. Furthermore miR-17 and miR-20a 
were found to be significantly associated with reduced progression free survival in 
gastrointestinal cancer patients [108] . 
The team led by Joan Massague [109] found that miR-335, miR-126, and miR-206 are 
metastasis-suppressors. Authors performed array-based miRNA profiling in MDA-MB-231 
breast cancer cell derivatives (LM2) highly breast cancer cell derivatives highly metastatic to 
bone and lung, and found a signature of six genes (miR-335, miR-126, miR-206, miR-122a, 
miR-199a*, and miR-489) whose expression was highly decreased in metastatic cells. 
Restoring the expression of miR-335, miR-126 or miR-206 in LM2 cells decreased the lung 
colonizing activity of these cells by more than fivefold. They found that miR-335 suppresses 
metastasis and migration by targeting the progenitor cell transcription factor SOX4 and TNC 
messenger RNAs. Consequently, loss of miR-335 leads to the activation of SRY-box containing 
SOX4 and TNC, which are responsible for the acquisition of metastatic properties. Notably, 
knockdown of SOX4 and TNC using RNA interference diminished in vitro invasive ability and 
in vivo metastatic potential, evidencing that both genes are key effectors of metastasis [110]. 
miR-126, has recently been described to suppress metastatic endothelial recruitment, 
metastatic angiogenesis and metastatic colonization through coordinate targeting of IGFBP2, 
PITPNC1 and MERTK, novel pro-angiogenic genes and biomarkers of human metastasis 
through the IGFBP2/IGF1/IGF1R and GAS6/MERTK signaling pathways [111]. In addition, 
low expression of miR-335 or miR-126 in primary tumors from patients was associated with 
poor distal metastasis-free survival. 
IGF1R was identified as a direct target of miR-493 that has been described as a metastasis 
inhibitor. Indeed, high levels of miR-493 and miR-493(*), but not pri-miR-493, in primary 
colon cancer were inversely related to the presence of liver metastasis, and attributed to an 
increase of miR-493 expression during carcinogenesis [112]. 
Raf kinase inhibitor protein (RKIP) represses breast tumour cell intravasation and bone 
metastasis through inhibition of MAPK leading to decreased transcription of LIN28 by Myc. 
Suppression of LIN28 enables enhanced let-7 processing in breast cancer cells. let-7 appears 
to play a major role in regulating stemness however elevated let-7 expression inhibits 
HMGA2, a chromatin remodelling protein that activates pro-invasive and pro-metastatic 
genes, including Snail. LIN28 depletion and let-7 expression suppress bone metastasis, and 
LIN28 restores bone metastasis in mice bearing RKIP-expressing breast tumour cells [113]. 
miR-146a is very similar to miR-146b, which is encoded by a different gene, but differs by 
only two bases and appears to function redundantly in many systems as mediators of 
inflammatory signaling, influencing differentiation, proliferation and apoptosis. They are 
pleiotropic regulators of tumorigenesis, as altered expression of both miR-146a/b have been 
linked with cancer risk, tumor histogenesis and invasive and metastatic capacity in diverse 
cancers [114]. In fact Hurst and coworkers [27], showed that breast cancer metastasis 
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suppressor 1 (BRMS1), a protein that regulates expression of multiple genes [115] leading to 
suppression of metastasis, significantly up-regulates miR-146a and miR-146b in metastatic 
breast cancer cells. Transduction of miR-146a or miR-146b into MDA-MB-231 inhibited 
invasion and migration in vitro, and suppressed experimental lung metastasis. Bhaumik et 
al. confirmed that expression of miR-146a/b in MDA-MB-231 cells, impaired invasion and 
migration capacity by suppressing NF-κB activity [116]. In Table 2 both suppressing and 
promoting metastasis related miRNAs are summarized. 
 
miRNA Target 
Suppressing miRNAs 
miR-17/20   
miR-23b 
miR-29b  
miR-29c   
miR-30a 
miR-31   
miR-34a   
miR-122   
miR-126  
miR-139   
miR-145   
miR-146a,b   
miR-148a 
miR-155  
miR-183  
miR-193a,b 
miR-203 
miR-205  
miR-335   
let-7   
miR-200 family  
miR-328 
miR-373/520c 
miR-493 
 
Promoting miRNAs 
miR-9  
miR-10b  
miR-17-92 
miR-21  
miR-27 
miR-103/107 
miR-221/222  
miR-223 
 
IL8, Cyclin D1 
c-MET, uPA  
COL1A1,COL4A1, MMP-2  
Laminin γ1, collagens  
Snail 
Integrin α5, Radixin, Rho A 
Snail, CD44, c-MET  
ADAM17 
ADAM9, Crk, IGFBP2, PTPNC1, MERTK  
ROCK2  
Mucin 1, N-cadherin, VEGF 
NF-κB  
ROCK 
Rho A 
Ezrin  
uPA  
Slug, Snail1 
ZEB1, ZEB2  
SOX4, TNC  
HMGA2, RAS  
ZEB1, ZEB2  
CD44 
CD44, TGFBR2 
IGF1R 
 
 
E-cadherin  
HOXD10 
CTGF, TSP1   
PDCD4 
APC 
Dicer 
TRPS1 
EPB41L3, FBXW7 
Table 2. microRNAs and their targets relevant in metastasis. 
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5. miRNAs as prognostic biomarkers 
After early studies indicating the role of microRNA genes in the pathogenesis of human 
cancer, platforms to assess the global expression of microRNA genes in normal and diseased 
tissues have been developed. Gene expression profiling has already demonstrated its 
effectiveness at subtyping various cancers, however miRNA profiles are equally 
discriminatory and can even be more informative, as changes in their expression can provide 
insights into the myriad of gene permutations observed in various cancer subtypes: links have 
indeed been made between misregulated miRNAs and the target genes that are affected, thus 
unraveling some of the unique gene networks involved [117]. miRNA profiles may identify 
cancer-specific signatures distinguishing between normal and cancerous tissue [118-121], but 
they can also discriminate different subtypes of a particular cancer [119,122,123].  
To discover microRNAs regulating the critical transition from ductal carcinoma in situ to 
invasive ductal carcinoma, a key event in breast cancer progression, Volinia et al. [124] 
performed a microRNA profile on 80 biopsies from invasive ductal carcinoma, 8 from ductal 
carcinoma in situ, and 6 from normal breast selected from a recently published deep-
sequencing dataset [125]. They found that the microRNA profile established for the normal 
breast to ductal carcinoma in situ transition was largely maintained in the in situ to invasive 
ductal carcinoma transition. Nevertheless, a nine-microRNA signature that differentiated 
invasive from in situ carcinoma was identified. Specifically, let-7d, miR-210, and -221 were 
down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an 
expression reversal along the cancer progression path. Additionally, they identified 
microRNAs for overall survival and time to metastasis. Five noncoding genes were 
associated with both prognostic signatures miR-210, -21, -106b*, -197, and let-7i, with miR-
210 the only one also involved in the invasive transition.  
Concerning the possibility to use miRNAs as prognostic markers to predict outcome, several 
groups have successfully addressed this issue [123,126-130] and in particular, concerning 
involvement of microRNAs in metastatic disease. For example several studies conducted on 
samples from patient with lung cancer assessed the involvement of metastamiRs: Landi et al 
[122] analyzed 107 male with early-stage squamous cell lung cancers (SQ) and found 5 
miRNAs (miR-25, -34c-5p, -191, let- 7e, miR-34a) whose high expression strongly predicted 
longer SQ survival [122]. In another study, based on miRNA expression profiling of lung 
adenocarcinoma and SQ, ten miRNAs (hsa-miR-450b-3p, hsa-miR-29c*, hsa-miR-145*, hsa-
miR-148a*, hsa-miR-1, hsa-miR-30d, hsa-miR-187, hsa-miR-218, hsa-miR-708* and hsa-miR-
375) associated with brain metastasis were identified including miR-145*, which inhibit cell 
invasion and metastasis. Two miRNA signatures that are highly predictive of recurrence 
free survival of 357 stage I NSCLC were also identified, one independent of cancer subtype, 
the other specific for adenocarcinoma or SQ subtype [131]. From a small cohort of 20 NSCLC 
patients, Donnem and co-workers [132] in addition to miR differentially expressed between 
NSCLC tumors and normal control, found 37 miRs up/down regulated in tumors derived 
from patients with short versus long disease specific survival (DSS) including upregulated 
miR-31, miR-183, let-7a, miR-193b and downregulated miR-205, miR-378, miR-708 and miR-
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29c. A further analysis comparing short versus long DSS patients tumors identified 
significantly altered angiogenesis-related miRs (miR-21, miR-106a, miR-126, miR-155, miR-
182, miR-210 and miR-424) [123], on the basis of a small number of cases, found that the 
reduced expression of miR-17-5p and -30c in malignant mesothelioma correlated with better 
survival in patients with the sarcomatoid subtype.  
Studies relative to tumors in other body districts have been carried out to determine the 
involvement of miRs in metastatic disease. Heinzelman et al, analysed miRNA expression of 
30 human clear cell renal carcinoma (ccRCC) including 10 non-metastatic tumors, 4 tumors 
with metastasis after 3 years or later and 4 tumors with primary metastasis. They detected a 
miRNA signature that distinguishes between metastatic and non-metastatic ccRCC, including 
miR-451, miR-221, miR-30a, miR-10b and miR-29a. Furthermore, the authors identified a 
group of 12 miRNAs, such as let-7 family, miR-30c, miR-26a, which are decreased in highly 
aggressive primary metastatic tumours. They found also correlations between expression 
levels of specific miRNAs with progression-free survival and overall survival [133].  
Veerla et al [95], by miRNA expression analysis of 34 cases of urothelial carcinomas 
identified 51 miRNAs that discriminated the 3 pathological subtypes Ta, T1 and T2-T3. A 
score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors 
with high precision and sensitivity. miRNAs showing high expression in muscle invasive 
tumors included miR-222 and miR-125b and in Ta tumors miR-10a. Moreover authors 
identified 2 miRNAs, miR-452 and miR-452*, associated with metastases in the lymph nodes 
and with a strong prognostic impact on death as endpoint. 
353 gastric samples from two independent subsets of patients from Japan were analysed by 
Ueda et al [119], with the aim to assess the relation between microRNA expression and 
prognosis of gastric cancer. They found a progression-related signature including miR-125b, 
miR-199a, and miR-100 as the most important microRNAs involved. Moreover they found 
that low expression of let-7g and miR-433 and high expression of miR-214 were associated 
with unfavourable outcome in overall survival independent of clinical covariates, including 
depth of invasion, lymph-node metastasis, and stage. 
6. Conclusion 
Although miRs that have been demonstrated to be implicated in the metastatic process 
might represent a possible therapeutic tool, there have been so far few reported successes in 
the development of miRNAs for use in therapy. There are two main strategies to target 
miRNAs expression in cancer. Direct strategies involve the use of oligonucleotides or virus-
based constructs to either block the expression of an oncogenic miRNA or to reintroduce a 
tumor suppressor miRNA lost in cancer. The indirect strategy involves the use of drugs to 
modulate miRNAs expression by targeting their transcription and their processing. Indeed, 
even though a number of reports have described the possibility to reintroduce or inhibit 
microRNAs (reviewed by Iorio and Croce, [134]), there are still many issues that need to be 
addressed for an effective translation in clinics, as the development of efficient methods of a 
specific drug delivery, and the accurate prevision of putative unwanted off target effects.  
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Nevertheless, the results obtained up to date seem quite promising and encouraging, and 
even though we still have to improve the knowledge in microRNA field to even think of 
future therapeutic applications, we might be not so far from there. 
Author details 
Tiziana Triulzi, Elda Tagliabue* and Patrizia Casalini 
Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, 
Fondazione IRCCS , Istituto Nazionale dei Tumori, Milan; Italy 
Marilena V. Iorio  
Start-Up Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS , 
Istituto Nazionale dei Tumori, Milan; Italy 
Acknowledgement 
Authors gratefully acknowledge Dr. Viola Regondi for figures preparation. 
7. References 
[1] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 Jan 
23;116:281-97. 
[2] Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in 
metastatic sites. Nat Rev Cancer 2002 Aug;2:563-72. 
[3] Bhayani MK, Calin GA, Lai SY. Functional relevance of miRNA sequences in human 
disease. Mutat Res 2012 Mar 1;731(1-2):14-9. 
[4] Su H, Trombly MI, Chen J, Wang X. Essential and overlapping functions for 
mammalian Argonautes in microRNA silencing. Genes Dev 2009 Feb 1;23(3):304-17. 
[5] Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein 
mRNAs and enhances their translation. Mol Cell 2008 May 23;30(4):460-71. 
[6] Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-
binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A 2007 Jun 
5;104(23):9667-72. 
[7] Moretti F, Thermann R, Hentze MW. Mechanism of translational regulation by miR-2 
from sites in the 5' untranslated region or the open reading frame. RNA 2010 
Dec;16(12):2493-502. 
[8] Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, et al. miR-24 regulates apoptosis by targeting 
the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 2010 Feb 
25;5(2):e9429. 
[9] Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs 
can up-regulate translation. Science 2007 Dec 21;318(5858):1931-4. 
                                                                 
* Corresponding Author 
 
microRNA: New Players in Metastatic Process 407 
[10] Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. 
PLoS Biol 2005 Mar;3(3):e85. 
[11] Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell 2005 Jan 
14;120(1):15-20. 
[12] Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial 
microRNA target predictions. Nat Genet 2005 May;37(5):495-500. 
[13] Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets 
and expression. Nucleic Acids Res 2008 Jan;36(Database issue):D149-D153. 
[14] Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved 
targets of microRNAs. Genome Res 2009 Jan;19(1):92-105. 
[15] Beitzinger M, Meister G. Preview. MicroRNAs: from decay to decoy. Cell 2010 Mar 
5;140(5):612-4. 
[16] Khraiwesh B, Arif MA, Seumel GI, Ossowski S, Weigel D, Reski R, et al. Transcriptional 
control of gene expression by microRNAs. Cell 2010 Jan 8;140(1):111-22. 
[17] Gonzalez S, Pisano DG, Serrano M. Mechanistic principles of chromatin remodeling 
guided by siRNAs and miRNAs. Cell Cycle 2008 Aug 15;7(16):2601-8. 
[18] Kim DH, Saetrom P, Snove O, Jr., Rossi JJ. MicroRNA-directed transcriptional gene 
silencing in mammalian cells. Proc Natl Acad Sci U S A 2008 Oct 21;105(42):16230-5. 
[19] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. 
[20] Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006 Nov 
17;127(4):679-95. 
[21] Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape 
mechanisms. Nat Rev Cancer 2003 May;3(5):362-74. 
[22] Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol 2010 
Jan 11;188(1):11-9. 
[23] Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, et al. 
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition 
after blocking of pericellular proteolysis. J Cell Biol 2003 Jan;%20;160(2):267-77. 
[24] Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin 
Invest 2009 Jun;119(6):1417-9. 
[25] Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr 
Opin Cell Biol 2003 Dec;15:740-6. 
[26] Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009 
Apr;9(4):285-93. 
[27] Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory 
microRNA is spreading. Cancer Res 2009 Oct 1;69(19):7495-8. 
[28] Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 
family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 
and SIP1. Nat Cell Biol 2008 May;10(5):593-601. 
[29] Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, et al. 
MicroRNA-200b Regulates Cell Proliferation, Invasion, and Migration by Directly 
Targeting ZEB2 in Gastric Carcinoma. Ann Surg Oncol 2012 Feb 4. 
 Oncogene and Cancer – From Bench to Clinic 408 
[30] Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, et al. Dynamic 
epigenetic regulation of the microRNA-200 family mediates epithelial and 
mesenchymal transitions in human tumorigenesis. Oncogene 2011 Aug 29;10. 
[31] Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, et al. Direct 
targeting of Sec23a by miR-200s influences cancer cell secretome and promotes 
metastatic colonization. Nat Med 2011 Aug 7;17(9):1101-8. 
[32] Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A 
MicroRNA targeting dicer for metastasis control. Cell 2010 Jun 25;141:1195-207. 
[33] Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-
activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. 
Nat Cell Biol 2009 Dec;11(12):1487-95. 
[34] Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, et al. Epigenetic Silencing of miR-203 
Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer 
Cells. Genes Cancer 2011 Aug;2(8):782-91. 
[35] Moes M, Le BA, Crespo I, Laurini C, Halavatyi A, Vetter G, et al. A Novel Network 
Integrating a miRNA-203/SNAI1 Feedback Loop which Regulates Epithelial to 
Mesenchymal Transition. PLoS One 2012;7(4):e35440. 
[36] Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, et al. 
MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is 
downregulated in non-small cell lung cancer. Int J Cancer 2012 May 1;130(9):2044-53. 
[37] Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human 
prostate carcinoma cell lines by targeting DVL2. Med Oncol 2011 Apr 13. 
[38] Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA. Prolonged 
mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen 
receptor by microRNAs. Breast Cancer Res Treat 2012 Feb;132(1):75-85. 
[39] Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. 
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor 
multifocality. Clin Cancer Res 2009 Aug 15;15(16):5073-81. 
[40] Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, et al. TRPS1 targeting by 
miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci 
Signal 2011 Jun 14;4(177):ra41. 
[41] Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA Families: 
Opposing Effects on Epithelial Identity. J Mammary Gland Biol Neoplasia 2012 
Mar;17(1):65-77. 
[42] Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs 
modulate the angiogenic properties of HUVECs. Blood 2006 Nov 1;108(9):3068-71. 
[43] Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, et al. microRNA-205 
regulates HER3 in human breast cancer. Cancer Res 2009 Mar 15;69:2195-200. 
[44] Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Tortoreto M, et al. 
Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol 
Oncol 2012;In press. 
[45] Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 
Exerts tumor-suppressive functions in human prostate through down-regulation of 
protein kinase Cepsilon. Cancer Res 2009 Mar 15;69:2287-95. 
 
microRNA: New Players in Metastatic Process 409 
[46] Dar AA, Majid S, de SD, Nosrati M, Bezrookove V, Kashani-Sabet M. miRNA-205 
suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 
protein. J Biol Chem 2011 May 13;286(19):16606-14. 
[47] Zhang Z, Liu S, Shi R, Zhao G. miR-27 promotes human gastric cancer cell metastasis by 
inducing epithelial-to-mesenchymal transition. Cancer Genet 2011 Sep;204(9):486-91. 
[48] Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, et al. miR-34 and 
SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal 
transitions. Cell Cycle 2011 Dec 15;10(24):4256-71. 
[49] Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion 
by down-regulation of c-Met expression in human hepatocellular carcinoma cells. 
Cancer Lett 2009 Mar 8;275:44-53. 
[50] Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a Inhibits the 
Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo. PLoS One 
2012;7(3):e33778. 
[51] Zhu L, Chen H, Zhou D, Li D, Bai R, Zheng S, et al. MicroRNA-9 up-regulation is involved 
in colorectal cancer metastasis via promoting cell motility. Med Oncol 2011 May 12. 
[52] Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic 
silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat 
Biotechnol 2010 Apr;28:341-7. 
[53] Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, et al. The molecular mechanism 
of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 
2012 Feb 27;10. 
[54] Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly 
targeting mucin 1. Cancer Res 2010 Jan 1;70:378-87. 
[55] Fan L, Wu Q, Xing X, Wei Y, Shao Z. MicroRNA-145 targets vascular endothelial 
growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim 
Biophys Sin (Shanghai) 2012 May;44(5):407-14. 
[56] Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a 
inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 
2011 Feb;17(2):211-5. 
[57] Huang Q, Gumireddy K, Schrier M, le SC, Nagel R, Nair S, et al. The microRNAs miR-
373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008 
Feb;10:202-10. 
[58] Wang CH, Lee DY, Deng Z, Jeyapalan Z, Lee SC, Kahai S, et al. MicroRNA miR-328 
regulates zonation morphogenesis by targeting CD44 expression. PLoS One 2008 Jun 
18;3(6):e2420. 
[59] Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in 
metastasis. Cell Res 2007 Jan;17(1):3-14. 
[60] Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, et al. 
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor 
negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. 
Oncogene 2011 Dec 12;10. 
 Oncogene and Cancer – From Bench to Clinic 410 
[61] Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N, et al. MiR-21 regulates EMT phenotype 
and HIF-1alpha expression in third-sphereforming breast cancer stem cell-like cells. 
Cancer Sci 2012 Mar 21;10-7006. 
[62] Noh H, Hong S, Dong Z, Pan ZK, Jing Q, Huang S. Impaired MicroRNA Processing 
Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen 
Activator Expression. Genes Cancer 2011 Feb;2(2):140-50. 
[63] Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-
type plasminogen activator (uPA) expression and tumor progression and invasion in 
human breast cancer. Oncogene 2009 Nov 5;28(44):3937-48. 
[64] Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P, et al. MicroRNA-23b 
mediates urokinase and c-met downmodulation and a decreased migration of human 
hepatocellular carcinoma cells. FEBS J 2009 Jun;276(11):2966-82. 
[65] Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, et al. microRNA 17/20 inhibits 
cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc 
Natl Acad Sci U S A 2010 May 4;107(18):8231-6. 
[66] Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. 
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 
and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 
2008 Apr 3;27:2128-36. 
[67] Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor 
genes in invasion and metastasis. Cell Res 2008 Mar;18:350-9. 
[68] Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, et al. MicroRNA-122, a tumor 
suppressor microRNA that regulates intrahepatic metastasis of hepatocellular 
carcinoma. Hepatology 2009 May;49(5):1571-82. 
[69] Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 
expression in liver cancer correlates with suppression of the hepatic phenotype and 
gain of metastatic properties. Oncogene 2009 Oct 8;28(40):3526-36. 
[70] Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J, et al. MiR-126 acts as a 
tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer 
Res 2012 Jan;10(1):3-10. 
[71] Feng R, Chen X, Yu Y, Su L, Yu B, Li J, et al. miR-126 functions as a tumour suppressor 
in human gastric cancer. Cancer Lett 2010 Dec 1;298(1):50-63. 
[72] Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, et al. MicroRNA-29b suppresses 
tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 
expression. Hepatology 2011 Nov;54(5):1729-40. 
[73] Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, 
and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 2010 Apr 
1;1(4):381-7. 
[74] Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, et al. 
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating 
mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 2008 Apr 
15;105(15):5874-8. 
 
microRNA: New Players in Metastatic Process 411 
[75] Pujuguet P, Del ML, Gautreau A, Louvard D, Arpin M. Ezrin regulates E-cadherin-
dependent adherens junction assembly through Rac1 activation. Mol Biol Cell 2003 
May;14(5):2181-91. 
[76] Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in 
breast cancer cells. BMC Cancer 2010 Sep 21;10:502.:502. 
[77] Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X, et al. Down-Regulation of miR-183 
Promotes Migration and Invasion of Osteosarcoma by Targeting Ezrin. Am J Pathol 
2012 Apr;%20. 
[78] Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer 
cells. FEBS Lett 2008 Oct 29;582(25-26):3663-8. 
[79] Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer 
invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 2011 
Jul;9(7):824-33. 
[80] Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, et al. 
Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal 
squamous cell carcinoma. Br J Cancer 2012 Jan 3;106(1):182-8. 
[81] Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by 
microRNA-10b in breast cancer. Nature 2007 Oct 11;449:682-8. 
[82] Nakata K, Ohuchida K, Mizumoto K, Kayashima T, Ikenaga N, Sakai H, et al. 
MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and 
correlates with a poor prognosis. Surgery 2011 Nov;150(5):916-22. 
[83] Liu Z, Zhu J, Cao H, Ren H, Fang X. miR-10b promotes cell invasion through RhoC-
AKT signaling pathway by targeting HOXD10 in gastric cancer. Int J Oncol 2012 
May;40(5):1553-60. 
[84] Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, et al. MicroRNA-10b is 
a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the 
Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells. Ann Surg Oncol 
2012 Feb 10. 
[85] Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is 
regulated by the transforming growth factor beta/Smad pathway and contributes to 
epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008 Nov;28(22):6773-84. 
[86] Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, et al. A 
pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009 
Jun 12;137(6):1032-46. 
[87] Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Activation of miR-31 
function in already-established metastases elicits metastatic regression. Genes Dev 2011 
Mar 15;25(6):646-59. 
[88] Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human 
microRNA genes are frequently located at fragile sites and genomic regions involved in 
cancers. Proc Natl Acad Sci U S A 2004 Mar 2;101:2999-3004. 
[89] Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs 
exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 
2006 Jun 13;103:9136-41. 
 Oncogene and Cancer – From Bench to Clinic 412 
[90] Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 
overexpression in human breast cancer is associated with advanced clinical stage, 
lymph node metastasis and patient poor prognosis. RNA 2008 Nov;14:2348-60. 
[91] Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic 
and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 
2010 Mar 1;126(5):1166-76. 
[92] Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, et al. Molecular 
profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation 
of serous ovarian carcinomas and other cancers. Cancer Res 2010 Mar 1;70(5):1906-15. 
[93] Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of 
microRNA species in human gastric cancer versus non-tumorous tissues. J 
Gastroenterol Hepatol 2009 Apr;24(4):652-7. 
[94] Zhang Y, Guo J, Li D, Xiao B, Miao Y, Jiang Z, et al. Down-regulation of miR-31 
expression in gastric cancer tissues and its clinical significance. Med Oncol 2010 
Sep;27(3):685-9. 
[95] Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, et al. MiRNA expression 
in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and 
miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int 
J Cancer 2009 May 1;124(9):2236-42. 
[96] Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification 
by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer 
and non-tumoral tissues. Mol Cancer 2006 Jul;%19;5:29.:29. 
[97] Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and 
under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009 
Apr;34(4):1069-75. 
[98] Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, et al. MicroRNA-223 is 
commonly repressed in hepatocellular carcinoma and potentiates expression of 
Stathmin1. Gastroenterology 2008 Jul;135(1):257-69. 
[99] Liu X, Chen Z, Yu J, Xia J, Zhou X. MicroRNA profiling and head and neck cancer. 
Comp Funct Genomics 2009. 
[100] Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, et al. miR-31 ablates expression of 
the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. 
Cancer Res 2010 Feb 15;70(4):1635-44. 
[101] Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential 
Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 2008 
May 1;14(9):2588-92. 
[102] Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving 
paradigms. Cell 2011 Oct 14;147(2):275-92. 
[103] Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses 
tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin 
Cancer Res 2011 Dec 15;17(24):7574-83. 
[104] Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, et al. The microRNA miR-
139 suppresses metastasis and progression of hepatocellular carcinoma by down-
regulating Rho-kinase 2. Gastroenterology 2011 Jan;140(1):322-31. 
 
microRNA: New Players in Metastatic Process 413 
[105] Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, et al. 
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad 
Sci U S A 2008 Sep 9;105(36):13556-61. 
[106] Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, et al. The myc-miR-17~92 
axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent 
antiangiogenic factors. Cancer Res 2010 Oct 15;70(20):8233-46. 
[107] Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase 
signaling prevents breast cancer metastasis to human bone. Cancer Res 2009 Nov 
15;69(22):8742-51. 
[108] Valladares-Ayerbes M, Blanco M, Haz M, Medina V, Iglesias-Diaz P, Lorenzo-Patino 
MJ, et al. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster 
deregulation in gastrointestinal cancer. Int J Oncol 2011 Nov;39(5):1253-64. 
[109] Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. 
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the 
lungs. Nat Med 2011 Jun 26;17(7):867-74. 
[110] Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous 
human microRNAs that suppress breast cancer metastasis. Nature 2008 Jan 10;451:147-52. 
[111] Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates 
endothelial recruitment and metastasis by cancer cells. Nature 2011 Dec 
14;481(7380):190-4. 
[112] Okamoto K, Ishiguro T, Midorikawa Y, Ohata H, Izumiya M, Tsuchiya N, et al. miR-
493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in 
liver. EMBO J 2012 Feb 28;31(7):1752-63. 
[113] Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf 
kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 
and let-7. EMBO J 2009 Feb 18;28(4):347-58. 
[114] Elsarraj HS, Stecklein SR, Valdez K, Behbod F. Emerging Functions of microRNA-
146a/b in Development and Breast Cancer : MicroRNA-146a/b in Development and 
Breast Cancer. J Mammary Gland Biol Neoplasia 2012 Mar;17(1):79-87. 
[115] Hurst DR, Welch DR. Unraveling the enigmatic complexities of BRMS1-mediated 
metastasis suppression. FEBS Lett 2011 Oct;%20;585(20):3185-90. 
[116] Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of 
microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in 
breast cancer cells. Oncogene 2008 Sep 18;27(42):5643-7. 
[117] O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast 
Cancer Res 2010;12(2):201. 
[118] Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, et al. Mirna expression 
profiles identify drivers in colorectal and pancreatic cancers. PLoS One 2012;7(3):e33663. 
[119] Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between 
microRNA expression and progression and prognosis of gastric cancer: a microRNA 
expression analysis. Lancet Oncol 2010 Feb;11(2):136-46. 
[120] Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. 
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in 
prostate cancer. Oncogene 2012 Feb 23;31(8):978-91. 
 Oncogene and Cancer – From Bench to Clinic 414 
[121] Schaefer A, Jung M, Miller K, Lein M, Kristiansen G, Erbersdobler A, et al. Suitable 
reference genes for relative quantification of miRNA expression in prostate cancer. Exp 
Mol Med 2010 Nov 30;42(11):749-58. 
[122] Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al. MicroRNA 
expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 
2010 Jan 15;16(2):430-41. 
[123] Busacca S, Germano S, De CL, Rinaldi M, Comoglio F, Favero F, et al. MicroRNA 
signature of malignant mesothelioma with potential diagnostic and prognostic 
implications. Am J Respir Cell Mol Biol 2010 Mar;42(3):312-9. 
[124] Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, et al. Breast cancer 
signatures for invasiveness and prognosis defined by deep sequencing of microRNA. 
Proc Natl Acad Sci U S A 2012 Feb 21;109(8):3024-9. 
[125] Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, et al. 
MicroRNA sequence and expression analysis in breast tumors by deep sequencing. 
Cancer Res 2011 Jul 1;71(13):4443-53. 
[126] du Rieu MC, Torrisani J, Selves J, Al ST, Souque A, Dufresne M, et al. MicroRNA-21 is 
induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010 
Apr;56(4):603-12. 
[127] Heneghan HM, Miller N, Kerin MJ. Circulating miRNA signatures: promising 
prognostic tools for cancer. J Clin Oncol 2010 Oct 10;28:e573-e574. 
[128] Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising 
novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010 Jul 
1;127(1):118-26. 
[129] Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer 
in sputum by a panel of microRNA markers. Mod Pathol 2010 Aug;23(8):1157-64. 
[130] Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures 
in tissues and plasma predict development and prognosis of computed tomography 
detected lung cancer. Proc Natl Acad Sci USA 2011 Mar 1;108:3713-8. 
[131] Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, et al. MicroRNA profiling 
and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 
2012 May;33(5):1046-54. 
[132] Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, et al. MicroRNA 
signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS 
One 2012;7(1):e29671. 
[133] Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, et al. 
Specific miRNA signatures are associated with metastasis and poor prognosis in clear 
cell renal cell carcinoma. World J Urol 2011 Jun;29(3):367-73. 
[134] Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and 
therapeutics. A comprehensive review. EMBO Mol Med 2012 Mar;4(3):143-59. 
